Barclays
KROS icon

Barclays’s Keros Therapeutics KROS Stock Holding History

Barclays’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$256K Sell
23,157
-51,569
-69% -$796K ﹤0.01% 3550
2025
Q4 		$1.52M Sell
74,726
-24,374
-25% -$428K ﹤0.01% 3124
2025
Q3 		$1.57M Sell
99,100
-22,030
-18% -$325K ﹤0.01% 3057
2025
Q2 		$1.62M Buy
121,130
+61,270
+102% +$827K ﹤0.01% 3018
2025
Q1 		$610K Sell
59,860
-47,682
-44% -$554K ﹤0.01% 3397
2024
Q4 		$1.7M Buy
107,542
+47,528
+79% +$2.47M ﹤0.01% 3020
2024
Q3 		$3.49M Buy
60,014
+35,022
+140% +$1.73M ﹤0.01% 2392
2024
Q2 		$1.14M Sell
24,992
-44,664
-64% -$2.4M ﹤0.01% 2523
2024
Q1 		$4.61M Sell
69,656
-190,104
-73% -$11.3M ﹤0.01% 1914
2023
Q4 		$10.3M Buy
259,760
+210,249
+425% +$6.59M ﹤0.01% 1494
2023
Q3 		$1.58M Buy
49,511
+11,118
+29% +$415K ﹤0.01% 2031
2023
Q2 		$1.54M Buy
38,393
+9,047
+31% +$397K ﹤0.01% 2052
2023
Q1 		$1.25M Sell
29,346
-8,589
-23% -$434K ﹤0.01% 2562
2022
Q4 		$1.82M Sell
37,935
-59,640
-61% -$2.79M ﹤0.01% 2320
2022
Q3 		$3.67M Buy
97,575
+63,658
+188% +$2.21M ﹤0.01% 1356
2022
Q2 		$936K Buy
33,917
+21,197
+167% +$930K ﹤0.01% 2420
2022
Q1 		$691K Buy
+12,720
New +$653K ﹤0.01% 2671

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Barclays's KROS Position: Q1 2026 in Review

Barclays reduced its Keros Therapeutics (KROS) stake by 69% in Q1 2026, selling an estimated $796K and leaving 23,157 shares worth $256K. The position accounts for ﹤0.01% of the portfolio, ranked #3550.

Barclays first reported a position in KROS in Q1 2022 and has held it in 17 quarters since. The position peaked at $10.3M in Q4 2023. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Barclays held 23,157 shares of Keros Therapeutics worth $256K as of Q1 2026.
  • Barclays sold 51,569 Keros Therapeutics shares in Q1 2026, an estimated $796K.
  • Keros Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3550 holding.
  • Barclays first reported a position in Keros Therapeutics in Q1 2022 and has held it in 17 quarters since.
  • Barclays's Keros Therapeutics position peaked at $10.3M in Q4 2023.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.